



SINO-EU
PerMed

Cooperation between China and Europe
in Personalised Medicine

Final Newsletter of Sino-EU PerMed

European and Chinese cooperation in personalised medicine research and implementation

Welcome to the final newsletter of the [SINO-EU PerMed](#) (Widening Sino-EU Policy and Research Cooperation in Personalised Medicine) project. The project focused on supporting [ICPerMed](#) (International Consortium for Personalised Medicine) towards Chinese partners as well as on reaching a common understanding of European and Chinese Personalised Medicine approaches.

For a last time, this newsletter will update you on our activities and achievements.

[Our project in a nutshell...](#)

Updates

Policy Briefs

New policy brief on ethical, legal and social aspects published

The Sino-EU PerMed project published its 2nd policy brief on ethical, legal and social aspects in the cooperation between Europe and China in Personalised Medicine. The policy brief is the result of the expertise by the ELSA Task Force that founded the project in 2023. It is also based on a

workshop and a delegation visit to China where discussions were held with other experts on this topic. The insights gained from these activities are to be seen as recommendations for both policy and science.

The document addresses three topics: 1.) Why is ELSA important for development and implementation of PM? 2.) Legal and regulatory aspects: the health data perspective, and 3.) Ethical and societal perspectives.

[More...](#)

[Link to ELSA Policy Brief](#)

Delegations

Sino-Eu PerMed Mission to China on ethical, legal and social aspects in Personalised Medicine

A delegation of experts in the field of ethical, legal, and social aspects in Personalised Medicine, alongside five project partners from the Sino-EU PerMed consortium, recently concluded a successful visit to China in April 2024. The visit, organised by DLR-PT in collaboration with Innovation Center Denmark, was a fact-finding mission focused on ELSA in the field of Personalised Medicine.

During their visit, the delegation had the opportunity to explore renowned Personalised Medicine research organisations, companies, and hospitals in Beijing, Guangzhou, and Shenzhen. Institutions visited included the Ethics Committee at Peking University, BeiGene, Novo Nordisk, Guangzhou Institutes for Biomedicine and Health, Sun Yat-sen University, Cancer Hospital, Hong Kong University Shenzhen Hospital, and BGI. The European experts who participated in the delegation came from Denmark, Germany, Great Britain, France, and Germany.

[More...](#)

Workshops

Sino-EU PerMed Workshop in Guangzhou on ethical, legal and social aspects in Personalised Medicine

The Sino-EU PerMed project recently held its final workshop in Guangzhou, China on 18 April 2024. This workshop focused on exploring the ethical, legal, and social aspects of Personalised Medicine in the collaboration between Europe and China. Experts from both regions came together to share their insights on this interdisciplinary topic. Throughout the workshop, examples from China and Europe were presented and discussed in relation to ethical, legal, and societal considerations. The event featured keynote and impulse talks, as well as in-depth discussions.

[More...](#)

Online

Sino-EU PerMed Database

The Sino-EU PerMed Database is now accessible online, providing a vital resource for researchers and stakeholders involved in Personalised Medicine in China and Europe. This database serves as a comprehensive repository of information on patents and publications. Offering an extensive collection of data, it enables users to stay up-to-date with the latest developments and trends. Furthermore, after two years since the previous mapping, the report has been recently updated. This update means an enhanced and more accurate representation of the landscape of Personalised Medicine in both regions.

[More...](#)

- [Link to Sino-EU PerMed Data Base](#)
- [Link to Updated Mapping](#)

New Publication

Based on the results of the second mapping, a scientific publication was written by our project partner Toscana Life Science. It describes the dynamics in the scientific-technological collaboration in Personalised Medicine between Europe and China especially over the last 3 years.

The pre-print article was published in medRxiv.

[Download publication](#)

End of Project

We would like to thank you very much for your interest in our project. An exciting journey characterised by a global pandemic and geopolitical challenges is now slowly coming to an end. However, we are pleased to inform you that the knowledge and results gained in this project will be further developed in the European Partnership for Personalised Medicine ([EP PerMed](#)) and also in [ICPerMed](#). If you are still interested in the topic and would like to follow the development of cooperation between Europe and China in Personalised Medicine, you should keep these two initiatives in mind.

ICPerMed stands for International Consortium for Personalised Medicine:

Its members are both public and private “not-for-profit” organisations, whose common aim is fostering PM development and research in the EU. The main decisional organ is the Executive Committee, supported by Challenge Groups and Action Item Groups in their action to implementing ICPerMed’s Action Plan.

About us

Our project within the ICPerMed Family



Cooperation between China and Europe
in Personalised Medicine

The Sino-EU PerMed project focuses on science and technology cooperation between China and the EU in the field of Personalised Medicine (PM).

The project aimed to identify PM-related research and health system stakeholders in Europe and China. It also pinpointed and addressed existing gaps, and analysed the potential and benefits of existing and new PM collaborations between Europe and China. In addition, Sino-EU PerMed aimed to establish links between relevant organisations and research centres that have an interest in PM research and innovation policy. Suitable and interested Chinese organisations were supported to participate in ICPerMed as well as in its working groups, workshops, conferences and other events and initiatives.

www.sino-eu-permed.eu

Sino-EU PerMed: This project received funding from the European Union’s Horizon 2020 Research and Innovation Programme und Grant Agreement No 874556.

Imprint

This newsletter is provided by:

DLR-PT

European and International Cooperation

Heinrich-Konen-Str. 1

53227 Bonn | Germany

E-mail: sino-eu-permed@dlr.de

For information about data protection, please see our [Privacy Policy](#).

To unsubscribe, please click [here](#).